Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DBV712 IHRP · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DBV712 Solution for Skin Prick Test | EXPERIMENTAL | DBV712 In-House Reference Skin Prick Test preparation |
| Name | Type | Description |
|---|---|---|
| DBV712 IHRP | DRUG | DBV712 Solution for Skin Prick Test |
Main Inclusion Criteria: * Male or female subjects aged between 12-50 years * Physician-diagnosed peanut allergy * Subject currently following a strict peanut-free diet * Documented history of positive test to peanut-specific IgE (ImmunoCAP system) \>0.7 kU/L * Positive peanut SPT with a largest wh...
DBV712 IHRP is an investigational small molecule being developed for the treatment of peanut allergy. It is intended for use in individuals with this condition, and it is currently in clinical development to assess its biological potency in adolescent and adult peanut allergic subjects.
DBV712 IHRP is being developed by DBV Technologies S.A., a biopharmaceutical company. The company is publicly traded under the ticker symbol DBVT on the stock market.
DBV712 IHRP is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
DBV712 IHRP has one completed clinical trial, identified as NCT03352726. This Phase 1 study was titled "A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects" and enrolled 27 participants in the United States.
DBV712 IHRP is being studied as a peanut allergen extract in clinical trials. The completed Phase 1 trial assessed the biological potency of peanut allergen extract in peanut allergic subjects, indicating that DBV712 IHRP is a form of peanut allergen extract.